PDZ and pleckstrin homology domains 1, pseudogeneGenealiases: []
Q-omics provides the consensus-scored PDZPH1P profile across patient tissues and cancer cell-line models. PDZPH1P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PDZPH1P is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, PDZPH1P RNA expression shows 7,805 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, BLCA, and GBM as cancer lineages where PDZPH1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDZPH1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDZPH1P survival associations across molecular data types. PDZPH1P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDZPH1P RNA expression–survival associations across cancer types. High PDZPH1P expression shows unfavorable associations in CESC, STAD, HNSC, KIRC, ACC and THYM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify CESC as the clearest survival context for PDZPH1P RNA expression.
This table summarizes PDZPH1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PDZPH1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDZPH1P shows lower tumor expression in BLCA, COAD and READ and higher tumor expression in KICH, LIHC and PRAD. The BLCA box plot shows higher PDZPH1P RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p < 0.001).
This table shows molecular features associated with PDZPH1P in patient tissues and cancer cell lines. In patient samples, PDZPH1P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
